<DOC>
	<DOCNO>NCT01555333</DOCNO>
	<brief_summary>This study enroll subject complete Protocols 209FX301 , 209FX302 , currently participate Protocol 2202 long-term study subject receive active drug ( arbaclofen ) .</brief_summary>
	<brief_title>An Open Label Extension Study Subjects With Fragile X Syndrome</brief_title>
	<detailed_description>Three study sponsor Seaside Therapeutics , Inc. , currently evaluate efficacy STX209 management typical problem behavior subject FXS . These Study 209FX301 , `` A Randomized , Double-Blind , Placebo-Controlled Study Efficacy , Safety , Tolerability STX209 ( Arbaclofen ) Administered Treatment Social Withdrawal Adolescents Adults Fragile X Syndrome ; '' Study 209FX302 , `` A Randomized , Double-Blind , Placebo-Controlled , Fixed- Dose Study Efficacy , Safety , Tolerability STX209 ( Arbaclofen ) Administered Treatment Social Withdrawal Children Fragile X Syndrome ; '' Study 22002 , `` An Open-Label Extension Study Evaluate Safety , Tolerability Pharmacokinetics STX209 Subjects Fragile X Syndrome . '' This study enroll subject complete Protocols 209FX301 , 209FX302 , currently participate Protocol 22002 long-term , open-label study . The open-label extension protocol provide data long-term safety tolerability STX209 among subject FXS receive treatment condition reflective typical medical care rather previously complete study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>1 . Successfully complete schedule visit previous protocol ( 22002 , 209FX301 , 209FX302 ) . 2 . A parent , LAR , caregiver must willing able accompany subject study visit , participate phone call , complete study assessment , administer study medication , report subject 's condition medication use site staff member . 3 . Prior conduct studyspecific procedure , subject must provide write informed consent participate study ( developmentally appropriate ) verbal assent parent/caregiver/LAR must provide write informed consent . If caregiver attend clinic visit parent , caregiver , LAR , write consent must also obtain caregiver 's participation study . 4 . Current treatment 3 psychoactive medication , include antiepileptic , unless Medical Monitor consult . 5 . Subjects history seizure disorder must seizure free 6 month take antiepileptic , seizure free 3 year receive antiepileptic treatment . If currently receive treatment antiepileptic , serum concentration level must test therapeutic range . 6 . Negative pregnancy test female childbearing potential use medically acceptable form birth control . Exclusion Criteria 1 . Subjects condition might interfere conduct study , confound interpretation study result , endanger wellbeing . This include , limited impairment renal function , evidence history malignancy significant hematological , endocrine , cardiovascular , respiratory , hepatic , gastrointestinal disease . 2 . Subjects currently engage illicit drug alcohol abuse . 3 . Subjects serious adverse event ( SAE ) take STX209 previous protocol ( 22002,209FX301,309FX302 ) Investigator consider related STX209 , unless approval Medical Monitor obtain . 4 . The occurrence continuation AE condition Studies 22002 , 209FX301 , 209FX302 , opinion Investigator , exclude subject participate openlabel extension . 5 . Subjects take another investigational drug , STX209 , currently within 30 day Visit 1 . Subject must take investigational drug study . 6 . Subjects , Investigator 's opinion , might suitable study . 7 . Subjects treat vigabatrin , tiagabine , riluzole currently within 2 week Visit 1 . 8 . Subjects treat racemic baclofen currently within 1 week Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>